Bio Farma: Indofarma Transformation Shows Positive Results

State-owned pharmaceutical giant PT Bio Farma (Persero) has announced that its ongoing transformation initiatives at PT Indofarma (Persero) Tbk are beginning to show positive outcomes. The overhaul focuses on efficiency, cost management, governance, and operational optimization as part of a broader agenda for the Bio Farma Group, which oversees state-owned pharmaceutical enterprises.

Shadiq Akasya, President Director of Bio Farma, stated that the transformation across all Bio Farma Group entities is not merely about short-term performance but also about establishing a robust and sustainable business foundation. Bio Farma is committed to driving continuous improvement in its subsidiaries and affiliates to bolster governance, enhance operational discipline, optimize assets and business capacity, and foster healthier business competitiveness.

"Bio Farma continues to drive transformation and sustainable improvements across all subsidiaries and affiliates to strengthen governance, operations, and business competitiveness," Shadiq explained. "At Indofarma, improvement measures have shown positive developments through efficiency, cost control, and operational optimization. This commitment is part of the Bio Farma Group's efforts to support the strengthening of national health resilience and contribute to Indonesia's health industry globally."

Akasya stressed that strong governance and operational discipline are crucial for navigating the increasingly complex healthcare industry. Bio Farma will continue to oversee the transformation process by enhancing accountability, optimizing portfolios and assets, strengthening production capabilities, and developing businesses aligned with market needs and national health priorities.

The Bio Farma Group also plans to enhance synergy among its entities to create a more integrated, resilient, and competitive healthcare industry ecosystem. This approach is expected to ensure the sustainability of all group members while strengthening the Indonesian pharmaceutical industry's contribution to national health resilience and global competitiveness.

“

Bio Farma continues to drive transformation and sustainable improvements across all subsidiaries and affiliates to strengthen governance, operations, and business competitiveness. At Indofarma, improvement measures have shown positive developments through efficiency, cost control, and operational optimization. This commitment is part of the Bio Farma Group's efforts to support the strengthening of national health resilience and contribute to Indonesia's health industry globally.